Johnson & Johnson Posts Upbeat Q2: IM Momentum Building Into 2027, Says Bullish Analyst

RBC reiterates an Outperform on Johnson & Johnson with a $287 price target, citing Innovative Medicine ex-Stelara growth of >14% YoY and the momentum building toward 2027. Key updates include Tremfya reaching ~$2B in Q2 sales (+71% YoY) and Tecvayli up 56% YoY, alongside oncology launch strength (e.g., Icotyde to 11,000 patients; INLEXZO insertions +75% sequentially). Despite a post-earnings stock pullback tied to MedTech cardio weakness, RBC expects a MedTech recovery in 2H 2026, while JNJ shares were up 0.84% to $249.09 at publication.

Analysis

The market is still pricing JNJ as a defensive compounder, but the real inflection is that the innovative-drug engine is now large enough to change the company’s multiple if it stays visible for several quarters. That matters because growth is increasingly broad-based rather than a single-product story, which reduces the odds that a lone asset reset derails the thesis. The competitive read-through is less about one winner and more about pressure on smaller oncology and immunology players whose sales forces and launch breadth cannot match a scaled platform.

Near term, I would not pay up into the strength: the stock likely needs proof that MedTech is a timing issue rather than a share-loss issue. The next 1-3 months are about whether launch metrics keep compounding and whether management sounds more confident on 2026 procedure trends; if either slows, the stock can stay boxed in despite strong drug growth. Over 6-18 months, the setup improves materially if the mix shift continues, because JNJ can re-rate from an income proxy toward a higher-quality growth defensive.

The contrarian risk is that consensus may be extrapolating launch momentum too linearly. The key falsifier is any step-down in ex-Stelara growth toward high-single digits, or evidence that MedTech weakness spreads beyond one pocket and delays the recovery narrative. If that happens, the market will likely compress the multiple before the 2027 story fully matures; if not, JNJ has room to outperform on both earnings revision and multiple expansion.

Key Decisions for Investors

• Buy JNJ on post-earnings weakness or on dips below the current trading range; 6-12 month upside is toward the low- to mid-280s if IM stays mid-teens and MedTech stabilizes.
• Pair trade: long JNJ / short MDT over 1-3 months to express the view that JNJ’s cardio softness is temporary while broader portfolio strength is underappreciated; stop if MedTech commentary turns clearly positive.
• Consider a Jan-2027 JNJ 260/300 call spread if implied vol is reasonable; this targets the 2027 re-rating story with defined risk and avoids overpaying for near-term noise.
• Set an alert on ex-Stelara growth and launch uptake: if either decelerates meaningfully in the next two quarters, reassess the long case because the market will likely compress the premium before guidance can catch up.